Capecitabine and vasospastic angina: a clinical case
https://doi.org/10.18087/cardio.2022.2.n1708
Abstract
The article presents a clinical case of a 78-year-old female patient with a clinical picture of vasospastic angina during the capecitabin treatment. The issues under discussion include difficulties of diagnosing vasospastic angina, a potential danger and incidence of coronary vasospastic reactions during chemotherapy with drugs of this group, and current approaches to prevention and correction of fluoropyrimidine cardiotoxicity. The presented clinical case confirms that vasospasm is a manifestation of capecitabin cardiotoxicity. This case also illustrates the importance of interaction and co-ordination of the work of oncologists and cardiologists at all stages of care of oncological patients.
Supporting agencies: No conflict of interest is reported.
About the Authors
I. P. Kolos
Medical Center of the Federal Property Management Agency, Moscow, Russia
Russian Federation
Russian Federation
V. A. Chernyshova
N.I. Pirogov Municipal Clinical Hospital #1, Moscow, Russia
Russian Federation
Russian Federation
E. V. Konstantinova
N.I. Pirogov Municipal Clinical Hospital #1, Moscow, Russia
"Pirogov Russian National Research Medical University", Moscow, Russia
Russian Federation
Russian Federation
M. Yu. Gilyarov
N.I. Pirogov Municipal Clinical Hospital #1, Moscow, Russia
"Pirogov Russian National Research Medical University", Moscow, Russia
Russian Federation
Russian Federation
References
1. Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers. 2010;2(3):1717–30. DOI: 10.3390/cancers2031717
2. Silverstein RA, González de Valdivia E, Visa N. The Incorporation of 5-Fluorouracil into RNA Affects the Ribonucleolytic Activity of the Exosome Subunit Rrp6. Molecular Cancer Research. 2011;9(3):332–40. DOI: 10.1158/1541-7786.MCR-10-0084
3. Jurczyk M, Król M, Midro A, Kurnik-Łucka M, Poniatowski A, Gil K. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. Journal of Clinical Medicine. 2021;10(19):4426. DOI: 10.3390/jcm10194426
4. Obedinskiy A.A., Bugurov S.V., Krestyaninov O.V., Naryshkin I.A., Zubarev D.D., Grazhdankin I.O. et al. Modern diagnostic capabilities for vasospastic angina diagnostics (intracoronary provocative testing). Circulation Pathology and Cardiac Surgery. 2017;21(1):98–103. DOI: 10.21688/1681-3472-2017-1-98-103
5. Judenherc Haouzi A, Schwartz S, Liszka E. Coronary artery spasm following dobutamine stress echocardiogram. BMJ Case Reports. 2020;13(8):e235206. DOI: 10.1136/bcr-2020-235206
6. Song Y-J, Ha SJ, Lee DS, Bang W-D, Shin DG, Woo Y et al. Ergonovine Stress Echocardiography for the Diagnosis of Vasospastic Angina and Its Prognostic Implications in 3,094 Consecutive Patients. Korean Circulation Journal. 2018;48(10):906–16. DOI: 10.4070/kcj.2017.0395
7. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U et al. International standardization of diagnostic criteria for vasospastic angina. European Heart Journal. 2017;38(33):2565–8. DOI: 10.1093/eurheartj/ehv351
8. De Falco V, Napolitano S, Roselló S, Huerta M, Cervantes A, Ciardiello F et al. How we treat metastatic colorectal cancer. ESMO Open. 2020;4(Suppl 2):e000813. DOI: 10.1136/esmoopen-2020-000813
9. Allison JD, Tanavin T, Yang Y, Birnbaum G, Khalid U. Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. Cardiovascular Toxicology. 2020;20(4):437–42. DOI: 10.1007/s12012-020-09562-w
10. de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. Journal of Clinical Oncology. 1992;10(11):1795–801. DOI: 10.1200/JCO.1992.10.11.1795
11. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacology and Toxicology. 2014;15(1):47. DOI: 10.1186/2050-6511-15-47
12. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation. 1982;65(2):281–5. DOI: 10.1161/01.CIR.65.2.281
13. Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E et al. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC: CardioOncology. 2021;3(2):250–9. DOI: 10.1016/j.jaccao.2021.02.011
14. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al. Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue. Circulation. 2016;133(13):1272–89. DOI: 10.1161/CIRCULATIONAHA.115.018347
15. Teperikidis E, Boulmpou A, Charalampidis P, Tsavousoglou C, Giannakoulas G, Papadopoulos CE et al. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations. Acta Cardiologica. 2021;1–13. [Epub ahead of print]. DOI: 10.1080/00015385.2021.1873548
16. Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiology Clinics. 2019;37(4):399–405. DOI: 10.1016/j.ccl.2019.07.004
17. Perrino C, Schiattarella G, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G et al. Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. Current Vascular Pharmacology. 2014;12(1):106–16. DOI: 10.2174/157016111201140327163302
18. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemotherapy and Pharmacology. 1999;43(2):157–61. DOI: 10.1007/s002800050877
19. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S et al. 5-fluorouracil and cardiotoxicity: a review. Therapeutic Advances in Medical Oncology. 2018;10:175883591878014. DOI: 10.1177/1758835918780140
20. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer. 1993;71(2):493–509. DOI: 10.1002/1097-0142(19930115)71:2<493::aidcncr2820710235>3.0.co;2-c
21. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. et al. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Malignant tumors. 2019;9(3S2):609–27. DOI: 10.18027/2224-5057-2019-9-3s2-609-627
Review
For citations:
Kolos I.P., Chernyshova V.A., Konstantinova E.V., Gilyarov M.Yu. Capecitabine and vasospastic angina: a clinical case. Kardiologiia. 2022;62(2):36-41. (In Russ.) https://doi.org/10.18087/cardio.2022.2.n1708
Views:
1184
Email this article 
Post a Comment 
